PATENT CLAIM ANALYSIS

Application Number: 15942836
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-01
Patent Classification: ["424", "139100"]

Abstract:
The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

Claim (Index 29):
The method of  claim 1 , wherein the anti-IL-6 antibody or antibody fragment is administered to the patient with a frequency at most once per period of approximately four weeks.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 91.0
- Lexical Diversity: 1.45205
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14988337', '12624965', '14604305', '13780018', '12323066']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8388113879427682
- 35 USC 102 Novelty (BERT): 0.7026599992022764
- Combined Prediction Score: 0.825196249068719
- Mean Citation Score: 722.722028
- Max Citation Score: 739.6697
- Similarity Product: 722.4832370532989

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test